Tag: investment
-
Bellicum Pharma Lands $20M in Series B Finance Round
Bellicum Pharmaceuticals Inc. in Houston, Texas says today it has raised $20 million in series B financing, the second round of investment after initial start-up. The company develops vaccines designed to attack specific disease-producing cells, including those causing life-threatening disorders such as cancer. The privately-held Bellicum says current and new investors contributed to this investment…
-
GE, Carbon Trust to Partner on Clean Tech Start-Up Support
General Electric and the U.K. environmental organization Carbon Trust will collaborate on backing start-up companies in Europe focusing on clean technologies. The partnership comes as the share of European investment in clean energy has declined over the past five years. During the first 18 months of the partnership, the Carbon Trust and GE will identify…
-
Cancer Diagnostics Company Gains $5M in Early Round Funds
On-Q-ity in Waltham, Massachusetts, a developer of cancer diagnostics technology, says it has added $5 million in series B financing, the second round of funding after initial start-up. Participants in the round are Mohr Davidow Ventures, Atlas Ventures, and Physic Ventures, all of which are current investors in the company. On-Q-Ty — short for Oncology…
-
Devices, Industrial Biotech Lead 2012 Life Science Funding
Funding for privately-held life sciences companies worldwide in the first six weeks of 2012 shows medical device developers and industrial biotechnology companies attracting the most equity capital, but drug developers engaging in the largest number of financing deals. The report by life sciences venture capital firm Burrill and Company was released on Friday. Burrill reports…
-
InnoCentive Acquires London-Based OmniComplete
InnoCentive Inc. in Waltham, Massachusetts, a provider of open-innovation and crowdsourcing competitions, says it has acquired OmniCompete Limited based in London, U.K. that also conducts challenge contests. No financial terms were disclosed. InnoCentive says it plans to adds OmniComplete’s experience in big-ticket competitions to InnoCentive’s so-called Grand Challenges, contests with larger payouts. Among the larger…
-
Venture Investment for European Companies Drops in 2011
Venture capital declined 14 percent and number of deals dropped 19 percent for European companies in 2011 compared to 2010, with €4.4 billion ($US 5.8 billion) going into 1,012 deals. Industries based on scientific discoveries were among those suffering double-digit percentage declines from the previous year. Dow Jones VentureSource that compiled the data says it…
-
Knee Replacement Maker Lands $89M Series E Financing
ConforMIS Inc. in Burlington, Massachusetts, a developer of customized knee-replacement implant technology, has raised $89 million in a series E round of funding, the fifth investment cycle after start up. The privately held company says the investments were made by private equity funds, led by AGC Equity Partners and Axel Johnson Inc., along with government…
-
VC Company, Harvard Start Seed-Stage Fund
The Experiment Fund, a joint venture of Harvard University’s engineering school and venture capital company New Enterprise Associates (NEA), opened today in Cambridge, Massachusetts. The fund plans to support technology-based student start-ups in Cambridge and companies begun elsewhere by former students. The venture expects to support companies working in information technologies, health care, and energy.…
-
Celgene to Acquire Avila Therapeutics
The pharmaceutical company Celgene Corp. in Summit, New Jersey says it will acquire Avila Therapeutics, a biotechnology company in Bedford, Massachusetts. Celgene discovers and commercializes therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Avila develops covalent drugs, those that bind to and inhibit disease-causing proteins. Under the agreement, Celgene…
-
Dutch Biotech Raises $30M for Rare Disease Therapies
Prosensa, a biopharmaceutical company in Leiden, the Netherlands, says it has raised €23 million ($30 million) in new equity financing. The company develops therapeutics using ribonucleic acid (RNA) modulation to address rare diseases, including Duchenne muscular dystrophy, myotonic dystrophy, and Huntington’s disease. The funding round is led by New Enterprise Associates in Menlo Park, California,…